v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) (MafA)

v-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MafA) is a basic leucine zipper (bZIP) transcription factor that serves as a master regulator of pancreatic beta-cell function and identity (UniProtKB - P61244). It binds specifically to the Maf recognition element (MARE), such as the RIPE3b/C1-element in the insulin gene promoter, to drive the expression of insulin and other key genes involved in glucose metabolism, including Glucokinase (GCK) and GLUT2 (SLC2A2) (PubMed: 15082708). MafA expression is restricted to mature beta-cells and is crucial for glucose-stimulated insulin secretion (GSIS); its loss is a hallmark of beta-cell exhaustion and dedifferentiation in Type 2 diabetes (PubMed: 21410918). Therapeutic interest in MafA focuses on its potential to restore beta-cell function in diabetic patients, either through gene therapy to re-introduce the factor or small molecules designed to stabilize the protein against degradation caused by oxidative stress (PubMed: 29030317). However, as a member of the Maf oncogene family, therapeutic modulation of MafA carries potential risks of oncogenesis and requires precise targeting to pancreatic tissues to avoid off-target effects (PubMed: 17496148).

Other names

Transcription factor MafARIPE3b1hMafAv-maf musculoaponeurotic fibrosarcoma oncogene homolog A

MafA binds to the Maf recognition element (MARE), specifically the RIPE3b/C1-element, within the promoter and enhancer regions of the insulin gene and other beta-cell specific genes to activate their transcription and maintain glucose homeostasis.